vs
Fidelity National Financial, Inc.（FNF）与INTEGRA LIFESCIENCES HOLDINGS CORP（IART）财务数据对比。点击上方公司名可切换其他公司
Fidelity National Financial, Inc.的季度营收约是INTEGRA LIFESCIENCES HOLDINGS CORP的1.3倍（$544.0M vs $434.9M），Fidelity National Financial, Inc.同比增速更快（10.3% vs -1.7%），过去两年Fidelity National Financial, Inc.的营收复合增速更高（13.7% vs 8.6%）
富达国民金融是美国财富500强企业，主要面向房地产与抵押贷款行业提供产权保险及交割服务，2019年其产权及房地产业务相关年度营收约为84.69亿美元，是全球领先的产权保险服务供应商。
英格拉生命科学控股是一家总部位于美国新泽西州普林斯顿的全球医疗器械企业，创立于1989年，主营皮肤再生、神经外科、重建外科与普通外科相关医疗器械。该公司开发的人工真皮是全球首款可规模化量产、用于治疗重度烧伤及其他皮肤创伤的人工皮肤组织。
FNF vs IART — 直观对比
营收规模更大
FNF
是对方的1.3倍
$434.9M
营收增速更快
FNF
高出12.1%
-1.7%
两年增速更快
FNF
近两年复合增速
8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $544.0M | $434.9M |
| 净利润 | $-117.0M | — |
| 毛利率 | — | 50.8% |
| 营业利润率 | 82.9% | 5.3% |
| 净利率 | -21.5% | — |
| 营收同比 | 10.3% | -1.7% |
| 净利润同比 | -126.0% | — |
| 每股收益（稀释后） | $-0.44 | $-0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNFIART
| Q4 25 | $544.0M | $434.9M | ||
| Q3 25 | $553.0M | $402.1M | ||
| Q2 25 | $547.0M | $415.6M | ||
| Q1 25 | $455.0M | $382.7M | ||
| Q4 24 | $493.0M | $442.6M | ||
| Q3 24 | $506.0M | $380.8M | ||
| Q2 24 | $504.0M | $418.2M | ||
| Q1 24 | $421.0M | $368.9M |
净利润FNFIART
| Q4 25 | $-117.0M | — | ||
| Q3 25 | $358.0M | $-5.4M | ||
| Q2 25 | $278.0M | $-484.1M | ||
| Q1 25 | $83.0M | $-25.3M | ||
| Q4 24 | $450.0M | — | ||
| Q3 24 | $266.0M | $-10.7M | ||
| Q2 24 | $306.0M | $-12.4M | ||
| Q1 24 | $248.0M | $-3.3M |
毛利率FNFIART
| Q4 25 | — | 50.8% | ||
| Q3 25 | — | 51.5% | ||
| Q2 25 | — | 50.4% | ||
| Q1 25 | — | 50.8% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 52.6% | ||
| Q2 24 | — | 54.0% | ||
| Q1 24 | — | 56.1% |
营业利润率FNFIART
| Q4 25 | 82.9% | 5.3% | ||
| Q3 25 | 81.9% | 2.9% | ||
| Q2 25 | 69.8% | -123.4% | ||
| Q1 25 | 24.4% | -4.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | 61.9% | -2.1% | ||
| Q2 24 | 90.9% | -0.7% | ||
| Q1 24 | 78.6% | 1.1% |
净利率FNFIART
| Q4 25 | -21.5% | — | ||
| Q3 25 | 64.7% | -1.3% | ||
| Q2 25 | 50.8% | -116.5% | ||
| Q1 25 | 18.2% | -6.6% | ||
| Q4 24 | 91.3% | — | ||
| Q3 24 | 52.6% | -2.8% | ||
| Q2 24 | 60.7% | -3.0% | ||
| Q1 24 | 58.9% | -0.9% |
每股收益（稀释后）FNFIART
| Q4 25 | $-0.44 | $-0.03 | ||
| Q3 25 | $1.33 | $-0.07 | ||
| Q2 25 | $1.02 | $-6.31 | ||
| Q1 25 | $0.30 | $-0.33 | ||
| Q4 24 | $1.65 | $0.25 | ||
| Q3 24 | $0.97 | $-0.14 | ||
| Q2 24 | $1.12 | $-0.16 | ||
| Q1 24 | $0.91 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.6B | $263.7M |
| 总债务越低越好 | $4.4B | $726.6M |
| 股东权益账面价值 | $7.4B | $1.0B |
| 总资产 | $109.0B | $3.6B |
| 负债/权益比越低杠杆越低 | 0.59× | 0.70× |
8季度趋势，按日历期对齐
现金及短期投资FNFIART
| Q4 25 | $2.6B | $263.7M | ||
| Q3 25 | $3.5B | $267.9M | ||
| Q2 25 | $3.3B | $253.6M | ||
| Q1 25 | $4.5B | $273.3M | ||
| Q4 24 | $3.5B | $273.6M | ||
| Q3 24 | $5.0B | $277.6M | ||
| Q2 24 | $4.9B | $296.9M | ||
| Q1 24 | $3.5B | $663.1M |
总债务FNFIART
| Q4 25 | $4.4B | $726.6M | ||
| Q3 25 | $4.4B | $736.3M | ||
| Q2 25 | $4.4B | $745.9M | ||
| Q1 25 | $4.4B | $755.6M | ||
| Q4 24 | $4.3B | $760.5M | ||
| Q3 24 | $4.2B | $765.3M | ||
| Q2 24 | $4.2B | $770.2M | ||
| Q1 24 | $3.9B | $775.0M |
股东权益FNFIART
| Q4 25 | $7.4B | $1.0B | ||
| Q3 25 | $8.4B | $1.0B | ||
| Q2 25 | $7.9B | $1.0B | ||
| Q1 25 | $7.9B | $1.5B | ||
| Q4 24 | $7.8B | $1.5B | ||
| Q3 24 | $8.1B | $1.5B | ||
| Q2 24 | $7.3B | $1.5B | ||
| Q1 24 | $7.1B | $1.6B |
总资产FNFIART
| Q4 25 | $109.0B | $3.6B | ||
| Q3 25 | $106.6B | $3.6B | ||
| Q2 25 | $102.3B | $3.7B | ||
| Q1 25 | $98.2B | $4.1B | ||
| Q4 24 | $95.4B | $4.0B | ||
| Q3 24 | $94.7B | $4.1B | ||
| Q2 24 | $88.8B | $4.1B | ||
| Q1 24 | $84.5B | $4.1B |
负债/权益比FNFIART
| Q4 25 | 0.59× | 0.70× | ||
| Q3 25 | 0.53× | 0.71× | ||
| Q2 25 | 0.56× | 0.72× | ||
| Q1 25 | 0.56× | 0.50× | ||
| Q4 24 | 0.56× | 0.49× | ||
| Q3 24 | 0.52× | 0.50× | ||
| Q2 24 | 0.58× | 0.50× | ||
| Q1 24 | 0.55× | 0.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.5B | $11.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-5.4M |
| 自由现金流率自由现金流/营收 | — | -1.2% |
| 资本支出强度资本支出/营收 | — | 4.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-31.1M |
8季度趋势，按日历期对齐
经营现金流FNFIART
| Q4 25 | $1.5B | $11.8M | ||
| Q3 25 | $1.3B | $40.9M | ||
| Q2 25 | $1.9B | $8.9M | ||
| Q1 25 | $1.1B | $-11.3M | ||
| Q4 24 | $1.5B | $50.7M | ||
| Q3 24 | $2.4B | $22.5M | ||
| Q2 24 | $1.4B | $40.4M | ||
| Q1 24 | $1.6B | $15.8M |
自由现金流FNFIART
| Q4 25 | — | $-5.4M | ||
| Q3 25 | — | $25.8M | ||
| Q2 25 | — | $-11.2M | ||
| Q1 25 | — | $-40.2M | ||
| Q4 24 | — | $21.1M | ||
| Q3 24 | — | $-7.2M | ||
| Q2 24 | — | $10.7M | ||
| Q1 24 | — | $291.0K |
自由现金流率FNFIART
| Q4 25 | — | -1.2% | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | — | -2.7% | ||
| Q1 25 | — | -10.5% | ||
| Q4 24 | — | 4.8% | ||
| Q3 24 | — | -1.9% | ||
| Q2 24 | — | 2.6% | ||
| Q1 24 | — | 0.1% |
资本支出强度FNFIART
| Q4 25 | — | 4.0% | ||
| Q3 25 | — | 3.8% | ||
| Q2 25 | — | 4.8% | ||
| Q1 25 | — | 7.6% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | — | 7.1% | ||
| Q1 24 | — | 4.2% |
现金转化率FNFIART
| Q4 25 | — | — | ||
| Q3 25 | 3.66× | — | ||
| Q2 25 | 6.82× | — | ||
| Q1 25 | 13.43× | — | ||
| Q4 24 | 3.32× | — | ||
| Q3 24 | 8.89× | — | ||
| Q2 24 | 4.45× | — | ||
| Q1 24 | 6.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FNF
| Escrow Fees | $241.0M | 44% |
| Other Title Related Fees And Income | $182.0M | 33% |
| Service Link Excluding Title Premiums Escrow Fees And Subservicing Fees | $87.0M | 16% |
| Insurance Contracts Home Warranty | $31.0M | 6% |
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
